These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17485754)

  • 1. Medicaid's prior authorization program and access to atypical antipsychotic medications.
    Polinski JM; Wang PS; Fischer MA
    Health Aff (Millwood); 2007; 26(3):750-60. PubMed ID: 17485754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
    Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
    Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A; Seymour L; Tackett R; Perri M
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?
    Fischer MA; Choudhry NK; Winkelmayer WC
    Health Aff (Millwood); 2007; 26(3):800-7. PubMed ID: 17485759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicaid policies to contain psychiatric drug costs.
    Koyanagi C; Forquer S; Alfano E
    Health Aff (Millwood); 2005; 24(2):536-44. PubMed ID: 15757941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Medicaid reimbursement rates on children's access to dental care.
    Nainar SM; Tinanoff N
    Pediatr Dent; 1997; 19(5):315-6. PubMed ID: 9260222
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2002.
    Johnson P
    Issue Brief Health Policy Track Serv; 2002 Dec; ():1-15. PubMed ID: 12877157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
    Law MR; Ross-Degnan D; Soumerai SB
    Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making the most of medicaid: promoting the health of women and infants with preconception care.
    Salganicoff A; An J
    Womens Health Issues; 2008; 18(6 Suppl):S41-6. PubMed ID: 18951816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.
    Lu CY; Soumerai SB; Ross-Degnan D; Zhang F; Adams AS
    Med Care; 2010 Jan; 48(1):4-9. PubMed ID: 19956079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics: considerations for Medicaid coverage.
    Surles RC
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S248-53. PubMed ID: 16180963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.
    Vogt WB; Joyce G; Xia J; Dirani R; Wan G; Goldman DP
    Health Aff (Millwood); 2011 Dec; 30(12):2346-54. PubMed ID: 22147863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid and indigent care issue brief: Medicaid: provider reimbursement.
    Johnson P
    Issue Brief Health Policy Track Serv; 2000 Jul; ():1-15. PubMed ID: 11073441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics.
    Duggan M
    J Health Econ; 2005 Jan; 24(1):1-31. PubMed ID: 15617786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.
    Roughead EE; Zhang F; Ross-Degnan D; Soumerai S
    Med Care; 2006 Apr; 44(4):378-82. PubMed ID: 16565640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.